RxDoctor Payments Data

Sandy Oh, MD

Internal Medicine · Arlington Heights, ILNPI 1851325203

Payments from drug & device makers

$7,112in general payments, 2019–2025

Across 359 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$679
  • AstraZeneca$669
  • Lilly USA, LLC$547
  • Boehringer Ingelheim$453
  • Novo Nordisk$420
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,05199%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,112 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$105,306
Medicare patients
426
Services billed
1,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$120,081
EliquisApixaban51$68,845
FarxigaDapagliflozin Propanediol41$44,198
MounjaroTirzepatide40$43,589
JardianceEmpagliflozin49$41,786
ProliaDenosumab13$23,840
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$13,562
Breo ElliptaFluticasone/Vilanterol17$8,127
Levothyroxine Sodium244$3,071
SynthroidLevothyroxine Sodium32$3,001
Rosuvastatin Calcium225$2,965
Atorvastatin Calcium284$2,472
Irbesartan117$2,364
Escitalopram Oxalate109$2,323
Amlodipine Besylate253$1,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$420$120,08195 claims
PfizerEliquis$331$68,84551 claims
AstraZenecaFarxiga$669$44,19841 claims
Lilly USA, LLCMounjaro$547$43,58940 claims
Boehringer IngelheimJardiance$453$41,78649 claims
AmgenProlia$1,028$23,84013 claims
GSKTrelegy Ellipta, Breo Ellipta$353$21,68928 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$36$3,071244 claims
AbbVieSynthroid$679$3,00132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →